At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating adalimumab and Placebo for Hidradenitis Suppurativa. Completed, enrolled 154 participants across 26 sites in 4 countries.
Detailed Summary
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesDenmark, Germany, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJun 2009
Primary CompletionMar 2010
Study CompletionNov 2010
TodayJul 2026
First PostedJun 11, 2009
Enrollment StartApr 1, 2009
Primary CompletionMar 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.1 years ago
Interventions
adalimumabbiological
Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
Placebodrug
Subcutaneous injection using prefilled syringe containing 0.8 milliliters